Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Halabi

Showing results (241-250 of 282) with videos related to

Pageof 29
Sort By:
The Lancet. Oncology|March 4, 2021
Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysisLaila A Gharzai, Ralph Jiang, David Wallington, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2016
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate CancerSusan Halabi, William Kevin Kelly, Hua Ma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2023
Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry StudyHerbert L Duvivier, Michael Rothe, Pam K Mangat, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2021
Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findingsUrsula M Vogl, Tomasz M Beer, Ian D Davis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2021
Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate CancerJamie M Sperger, Hamid Emamekhoo, Rana R McKay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 14, 2019
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY StudyAndrew J Armstrong, Susan Halabi, Jun Luo, et al.
JCO Precision Oncology|October 16, 2024
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyFrancis P Worden, Evan Pisick, Michael Rothe, et al.
JCO Precision Oncology|October 16, 2025
Olaparib in Patients With Solid Tumors With <i>BRCA1/2</i> Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) StudyTareq Al Baghdadi, Michael Rothe, Pam K Mangat, et al.
European Urology Open Science|August 2, 2021
Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision MedicineJuho Jasu, Teemu Tolonen, Emmanuel S Antonarakis, et al.
JCO Precision Oncology|April 22, 2026
Temsirolimus in Patients With Solid Tumors With <i>PIK3CA</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyEvan Pisick, Michael Rothe, Elizabeth Garrett-Mayer, et al.
Pageof 29

Showing results (241-250 of 282) with videos related to

Sort By:
Pageof 29
The Lancet. Oncology|March 4, 2021
Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysisLaila A Gharzai, Ralph Jiang, David Wallington, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2016
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate CancerSusan Halabi, William Kevin Kelly, Hua Ma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2023
Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry StudyHerbert L Duvivier, Michael Rothe, Pam K Mangat, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2021
Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findingsUrsula M Vogl, Tomasz M Beer, Ian D Davis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2021
Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate CancerJamie M Sperger, Hamid Emamekhoo, Rana R McKay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 14, 2019
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY StudyAndrew J Armstrong, Susan Halabi, Jun Luo, et al.
JCO Precision Oncology|October 16, 2024
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyFrancis P Worden, Evan Pisick, Michael Rothe, et al.
JCO Precision Oncology|October 16, 2025
Olaparib in Patients With Solid Tumors With <i>BRCA1/2</i> Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) StudyTareq Al Baghdadi, Michael Rothe, Pam K Mangat, et al.
European Urology Open Science|August 2, 2021
Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision MedicineJuho Jasu, Teemu Tolonen, Emmanuel S Antonarakis, et al.
JCO Precision Oncology|April 22, 2026
Temsirolimus in Patients With Solid Tumors With <i>PIK3CA</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyEvan Pisick, Michael Rothe, Elizabeth Garrett-Mayer, et al.
Pageof 29